Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
· Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE^® (pegcetacoplan injection) and $91..
· Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE^® (pegcetacoplan injection) and $91..
WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^®..
The consortium of journalists behind the Pegasus Project investigation into malware from Israel-based NSO Group has won the first..